Synthesis, characterization, biodistribution and scintigraphy of 99mTc-paclitaxel: a potential tracer of paclitaxel

Journal of Radioanalytical and Nuclear Chemistry

Volumn 304, Issue 2, 2015, Pages 633-643

  Banerjee, Indranil ^a   Behera, Ashok ^a   De, Kakali ^a   Chattopadhyay, Sankha ^b   Sachdev, Satbir Singh ^c   Sarkar, Bharat ^d   Ganguly, Santanu ^d   Misra, Mridula ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b VARIABLE ENERGY CYCLOTRON CENTRE   (India)

^c Board of Radiation and Isotope Technology   (India)

^d Regional Radiation Medicine Centre Thakurpukur Cancer Research Centre   (India)

Author keywords

99mTc paclitaxel; Quantitative biodistribution; Scintigraphy; Sodium borohydride

Indexed keywords

EID: 84939970625     PISSN: 02365731     EISSN: 15882780     Source Type: Journal    
DOI: 10.1007/s10967-014-3825-3     Document Type: Article

References (39)

1. Pomper MG, Lee JS (2005) Small animal imaging in drug development. Curr Pharm Des 11:3247–3272
2. Franc BL, Acton PD, Mari C, Hasegawa BH (2008) Small-animal SPECT and SPECT/CT: important tools for preclinical investigation. J Nucl Med 49:1651–1663
3. Golestani R, Wu C, Tio RA, Zeebregts CJ, Petrov AD, Beekman FJ, Dierckx RA, Boersma HH, Slart RH (2010) Small-animal SPECT and SPECT/CT: application in cardiovascular research. Eur J Nucl Med Mol Imaging 37:1766–1777
4. Gomes CM, Abrunhosa AJ, Ramos P, Pauwels EK (2011) Molecular imaging with SPECT as a tool for drug development. Adv Drug Deliv Rev 63:547–554
5. Horwitz SB (1992) Mechanism of action of taxol. Trends Pharmacol Sci 13:134–136
6. Lin HL, Liu TY, Chau GY, Lui WY, Chi CW (2000) Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 89:983–994
7. http://www.clinicaltrials.gov/. Accessed 31 July 2014
8. Liu Y, Tseng YC, Huang L (2012) Biodistribution studies of nanoparticles using fluorescence imaging: a qualitative or quantitative method? Pharm Res 29:3273–3277
9. Behera A, Banerjee I, De K, Munda RN, Chattopadhayay S, Samanta A, Sarkar B, Ganguly S, Misra M (2012) Synthesis, characterization, conformational analysis of a cyclic conjugated octreotate peptide and biological evaluation of (99 m)Tc-HYNIC-His (3)-Octreotate as novel tracer for the imaging of somatostatin receptor-positive tumors. Amino Acids 44:933–946
10. De K, Bhowmik A, Behera A, Banerjee I, Ghosh MK, Misra M (2012) Synthesis, radiolabeling, and preclinical evaluation of a new octreotide analog for somatostatin receptor-positive tumor scintigraphy. J Pept Sci. doi:10.1002/psc.2458
11. Jain V, Swarnakar NK, Mishra PR, Verma A, Kaul A, Mishra AK, Jain NK (2012) Paclitaxel loaded PEGylated gleceryl monooleate based nanoparticulate carriers in chemotherapy. Biomaterials 33:7206–7220
12. Banerjee T, Mitra S, Kumar Singh A, Kumar Sharma R, Maitra A (2002) Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int J Pharm 243:93–105
13. Banerjee I, De K, Chattopadhyay S, Bandyopadhyay AK, Misra M (2014) An easy and effective method for radiolabelling of solid lipid nanoparticles. J Radioanal Nucl Chem. doi: 10.1007/s10967-014-3258-z
14. Theobald AE (1990) Textbook of radiopharmacy: theory and practice. Gorden and Breach, New York
15. Reddy LH, Sharma RK, Murthy RS (2004) Enhanced tumour uptake of doxorubicin loaded poly (butyl cyanoacrylate) nanoparticles in mice bearing Dalton’s lymphoma tumour. J Drug Target 12:443–451
16. Mishra AK, Iznaga-Escobar N, Figueredo R, Jain VK, Dwarakanath BS, Pérez-Rodríguez R, Sharma RK, Mathew TL (2002) Preparation and comparative evaluation of 99 mTc-labeled 2-Iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodies. Methods Find Exp Clin Pharmacol 24:653–660
17. http://www.britatom.gov.in/docs/rph_ria_cat/RPH_COLD/RPH_TCK7.pdf. Accessed 17 Oct 2014
18. 99mTc-Daunorubicin a potential brain imaging and theranostic agent: synthesis, quality control, characterization, biodistribution and scintigraphy. Nucl Med Biol 40:148–152
19. Gustafson DL, Long ME, Bradshaw EL, Merz AL, Kerzic PJ (2005) P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing. Cancer Chemother Pharmacol 56:248–254
20. Harivardhan Reddy L, Sharma RK, Chuttani K, Mishra AK, Murthy RS (2005) Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton’s lymphoma tumor bearing mice. J Control Release 105:185–198
21. Wenk MR, Fahr A, Reszka R, Seelig J (1996) Paclitaxel partitioning into lipid bilayers. J Pharm Sci 85:228–231
22. Zolle I (2007) Technetium-99 m pharmaceuticals: preparation and quality control in nuclear medicine. Springer, Berlin
23. De K, Behera A, Banerjee I, Sarkar B, Ganguly S, Misra M (2014) Radiolabeled novel peptide for imaging somatostatin-receptor expressing tumor: synthesis and radiobiological evaluation. J Radioanal Nucl Chem. doi:10.1007/s10967-014-3199-6
24. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1998) Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 9:1–17
25. 18F]fluoropaclitaxel. Nucl Med Biol 34:823–831
26. Eckelman WC (2009) Unparalleled contribution of Technetium-99m to medicine over 5 decades. JACC Cardiovasc Imaging 2:364–368
27. Li C, Yu DF, Inoue T, Yang DJ, Tansey W, Liu CW, Milas L, Hunter NR, Kim EE, Wallace S (1997) Synthesis, biodistribution and imaging properties of indium-111-DTPA-paclitaxel in mice bearing mammary tumors. J Nucl Med 38:1042–1047
28. 123I. Bioorg Med Chem 8:65–68
29. Banerjee T, Singh AK, Sharma RK, Maitra AN (2005) Labeling efficiency and biodistribution of Technetium-99m labeled nanoparticles: interference by colloidal tin oxide particles. Int J Pharm 289:189–195
30. Halder KK, Nayak DK, Baishya R, Sarkar BR, Sinha S, Ganguly S, Debnath MC (2011) (99m)Tc-labeling of ciprofloxacin and nitrofuryl thiosemicarbazone using fac-[(99m)Tc(CO)3(H2O)3] core: evaluation of their efficacy as infection imaging agents. Metallomics 3:1041–1048
31. Jansen JA, Andersen J, Schou JS (1984) Boric acid single dose pharmacokinetics after intravenous administration to man. Arch Toxicol 55:64–67
32. http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500011109.pdf. Accessed 31 July 2014
33. http://packageinserts.bms.com/pi/pi_taxol.pdf. Accessed 31 July 2014
34. Koziara JM, Lockman PR, Allen DD, Mumper RJ (2004) Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 99:259–269
35. Sykes E, Woodburn K, Decker D, Kessel D (1994) Effects of Cremophor EL on the distribution of taxol to serum lipoproteins. Br J Cancer 70:401–404
36. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56:2112–2115
37. Scripture CD, Figg WD, Sparreboom A (2005) Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther Clin Risk Manag 1:107–114
38. Woodburn K, Chang CK, Lee S, Henderson B, Kessel D (1994) Biodistribution and PDT efficacy of a ketochlorin photosensitizer as a function of the delivery vehicle. Photochem Photobiol 60:154–159
39. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843–1849